This article was published on 7 November 2016
Tech Incubator support helps turn a great idea into a viable commercial proposition.
As of June 2016, WNT Ventures has invested in seven companies. One of these is Mastaplex: an innovative point-of-care diagnostic test kit for treatment of bovine mastitis. Bovine mastitis is a persistent, inflammatory reaction of cows’ udders often caused by bacterial infection. It halts milking while being treated. As it can be caused by a variety of pathogens, it can be hard to prescribe the correct antibiotic to cure it. Mastaplex can identify the specific bacteria, which means that the cow can get the right treatment from the start. This saves considerable time and dollars for vets and farmers.
Mastaplex founder Dr. Olaf Bork had been developing innovative products for treating bovine mastitis for six years before patenting his research and starting Mastaplex. Mastitis treatment is a fast-moving area, so getting the product to market quickly was vital. As his concept has flourished, Olaf has received a wide range of support, including an external mentor for business guidance and a tenancy at the University of Otago’s Centre for Innovation, which affords him access to infrastructure, facilities and other researchers. But Bork says that without the support of WNT Ventures and Callaghan Innovation, he simply wouldn’t have been able to keep the speed of development up
WNT Ventures is not here just for a few years – we are creating a long-term sustainable institution. To do that requires government support in the short term… Callaghan Innovation support is absolutely instrumental in us being around.– Carl Jones, CEO of WNT Ventures.
WNT Ventures CEO Carl Jones also acknowledges Callaghan Innovation’s support. “WNT Ventures invests at a highly risky stage in the market, which would be difficult without Callaghan Innovation. From repayable loans to access to their people and resources, their backing is critical – alongside WNT’s own people, networks and capital.
As Mastaplex moves towards product launch, they and the other WNT Ventures companies will get continued support from both the incubator and Callaghan Innovation to help them along the road to success.
How we helped
Through WNT Ventures and Callaghan Innovation, Mastaplex gained:
- funding to take a product to market
- expert knowledge and advice, access to domestic and international networks
- quality governance and board support
- promotional support
- training and development in IP strategy
Callaghan Innovation employs a 3:1 matching basis for incubator funding – meaning they match whatever WNT invest three times over in the form of a repayable loan.